Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA von Girvan, Allicia C, Carter, Gebra C, Li, Li, Kaltenboeck, Anna, Ivanova, Jasmina, Koh, Maria, Stevens, Jessi, Hayes-Larson, Eleanor, Lahn, Michael M

Volltext

Abstract P3-08-40: Prognostic factors associated with clinical outcomes in HR+, HER2- advanced breast cancer: Systematic literature review von Carter, Gebra C, Stenger, Keri, Mohanty, Maitreyee, Chong, Amy L, Basa, Pradeep, Singuru, Shivaprasad, Singh, Sheena, Tongbram, Vanita, Kümmel, Sherko, Guarneri, Valentina, Tolaney, Sara M

Volltext

Abstract A66: Recommendations to address common barriers to diversity in oncology clinical trials: An industry perspective von Kirsch, Kelly R., Carter, Gebra C., Cole, Jacqueline M., Girvan, Allicia C., Obasaju, Coleman K.

Volltext

Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review von Cuyún Carter, Gebra, Mohanty, Maitreyee, Stenger, Keri, Morato Guimaraes, Claudia, Singuru, Shivaprasad, Basa, Pradeep, Singh, Sheena, Tongbram, Vanita, Kuemmel, Sherko, Guarneri, Valentina, Tolaney, Sara M

Volltext

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score ® Test from a US Societal Perspective von Berdunov, Vladislav, Cuyun Carter, Gebra, Laws, Ewan, Luo, Roger, Russell, Christy A, Campbell, Sara, Abdou, Yara, Force, Jeremy

Volltext

Re: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer von Hess, Lisa M, Carter, Gebra, Smolen, Lee, Bowman, Lee, von Hohnhorst, Philipp, Seagle, Chris

Volltext